ClinicalTrials.gov
public full text
Public Domain
An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis
The aim of this case series was to document the effectiveness and compatibility of Rebif 44 or 22 µg in the therapy of the chronic multiple sclerosis (MS) under practical conditions on a large collection of subjects. In addition, the side effects possibly occurring in the initial phase of therapy and satisfaction of the subject as well as the treating doctor was also documented.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Rebif Compliance Support Program - Assessing Needs in Multiple Sclerosis#836747
- Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One#1104324
- MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS)#835995
- A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis#892192
- The Multicenter, Open-label, Single-use Autoinjector Convenience Study#1100683
Record · ID 868937
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive